Informax Announces the Release of Genomax Version 3.2.
Business Editors/Health & Medical Writers
BETHESDA, Md.--(BW HealthWire)--Nov. 7, 2001
InforMax, Inc. (Nasdaq:INMX), a leading global provider of bioinformatics software solutions, today announced the release of GenoMax(TM) version 3.2.
This new release contains significant enhancements to the GenoMax enterprise bioinformatics system, including the addition of Gene Expression Analysis II.
"Comprehensive and integrated software Separate software components or applications that have been combined into one package. See integrated software package. solutions are essential to enable sophisticated problem solving problem solving
Process involved in finding a solution to a problem. Many animals routinely solve problems of locomotion, food finding, and shelter through trial and error. , data mining and efficient analytical processes." said Stephen Lincoln, Chief Scientific Officer and Executive Vice President of Product Development at InforMax. "The ongoing development of our GenoMax enterprise bioinformatics system affirms InforMax's commitment to advance the science of bioinformatics through the delivery of unique software and services that improve both the efficiency and effectiveness of the target discovery and validation process."
GenoMax version 3.2 enhanced features include an innovative high-performance engine for GenBank data storage, accelerated initial data loading Copying data from one electronic file or database into another. Data loading implies converting from one format into another; for example, from one type of production database into a decision support database from a different vendor. See data entry. and indexing, improved administrative capabilities, and enhanced scripting to improve end-user productivity and reduce administrative costs administrative costs,
n.pl the overhead expenses incurred in the operation of a dental benefits program, excluding costs of dental services provided. .
Additionally, GenoMax version 3.2 includes numerous new features in the Sequence Analysis and Protein-Protein Interaction Protein-protein interactions refer to the association of protein molecules and the study of these associations from the perspective of biochemistry, signal transduction and networks.
The interactions between proteins are important for many biological functions. Analysis modules.
Gene Expression Analysis II, the next generation of GenoMax gene expression software, features newly designed data import utilities and additional data visualization See information visualization. tools, which allow detailed data quality verification and provide powerful annotation 1. (programming, compiler) annotation - Extra information associated with a particular point in a document or program. Annotations may be added either by a compiler or by the programmer. capabilities for analysis of gene function.
The Gene Expression Analysis II module supports diverse gene expression data formats and provides customers with the industry's most comprehensive solution for analyzing and understanding gene expression information.
"GenoMax and the sophisticated analytical capabilities in the Gene Expression Analysis II module are key enablers for our work here at the University of North Carolina North Carolina, state in the SE United States. It is bordered by the Atlantic Ocean (E), South Carolina and Georgia (S), Tennessee (W), and Virginia (N). Facts and Figures
Area, 52,586 sq mi (136,198 sq km). Pop. . The robust data import capabilities simplify the growing challenge of managing data commonly found with other gene expression analysis products," said David Fenstermacher, Director of Bioinformatics at the University of North Carolina.
Rapidly becoming the industry standard, GenoMax is an enterprise bioinformatics system that enables High-Throughput Research(TM) (HTR HTR Heater
HTR High Temperature Reactor
HTR Hunter: the Reckoning (White-Wolf game)
HTR Hemolytic Transfusion Reaction (blood transfusion)
HTR Hellenic Technology of Robotics ), InforMax's process for minimizing the time and cost of both discovering and validating valuable targets for pharmaceutical, therapeutic, and diagnostic development.
This modular family of tools is designed to work with one or more types of genomic genomic
pertaining to a genome.
the DNA sequences making up the genome of an individual.
see gene bank. and proteomic data, and includes Sequence, Gene Expression, 3D Structure, Protein-Protein Interaction and Genome Analysis modules.
InforMax is the leading global developer of bioinformatics software for High-Throughput Research(TM). Founded in 1990, InforMax products are used by over 1,800 research organizations and more than 28,000 individual scientists worldwide (as of September 30, 2001) to understand and extract value from the massive amounts of data being generated by the Genomic Revolution.
Among InforMax's customers are 23 of the top 25 pharmaceutical companies. InforMax's mission is to support the scientific community in drug discovery and to better understand the causes of disease.
Our comprehensive portfolio of bioinformatics software solutions help scientists increase the effectiveness and reduce the time and investment it takes to identify and validate biological targets and discover treatments for disease. InforMax bioinformatics software solutions enable a full range of gene-to-genome analysis, interpretation and data mining.
Our market-leading products include Vector NTI NTI NewTech Infosystems (software company, Irvine, California)
NTI Nuclear Threat Initiative
NTI National Transit Institute (New Brunswick, New Jersey)
NTI Nunavut Tunngavik Incorporated (R) Suite, the most widely used software suite for enhancing laboratory productivity, and GenoMax(TM), a modular family of analysis programs for integrated analysis of genomic and proteomic data. Additional information about InforMax can be found at our Web site at http://www.informaxinc.com.
Statements in this press release that are not strictly historical are "forward-looking" statements, which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements forward-looking statement
A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. .
Factors that could cause or contribute to differences include, but are not limited to, risks associated with the Company's operating losses operating loss
The excess of operating expenses over revenue. As with operating income, operating losses exclude revenues and expenses from operations that are not considered a regular part of the business. Also called deficit. Compare operating income. and accumulated deficit and the prospect that the Company may not achieve or maintain profitability in the future, the Company's dependence for future revenues and its ability to increase sales of its enterprise platform and successfully establish the GenoMax brand, any disruption to the Company's operations or increase in its administrative costs associated with the Company's current executive management search and management transition and risks associated with InforMax's technologies and the need to keep pace with rapid technological change.
These factors and others are more fully described in the Company's annual report on Form 10-K Form 10-K
A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information.
See 10-K. and the most recent 10-Q, as filed with the Securities and Exchange Commission. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company's current outlook only as of the date given.
InforMax, the InforMax logo, Vector NTI, AlignX, BioPlot, and ContigExpress are registered trademarks and GenoMax and High-Throughput Research are trademarks of InforMax, Inc. All other products or company names are used for identification purposes only, and may be the trademarks of their respective owners.